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Abstract
Background: A protocol for cervical cancer screening among sexually active women 25 to 65 years of age was
introduced in 2006 in Catalonia, Spain to increase coverage and to recommend a 3-year-interval between
screening cytology. In addition, Human Papillomavirus (HPV) was offered as a triage test for women with a
diagnosis of atypical squamous cells of undetermined significance (ASC-US). HPV testing was recommended within
3 months of ASC-US diagnosis. According to protocol, HPV negative women were referred to regular screening
including a cytological exam every 3 years while HPV positive women were referred to colposcopy and closer
follow-up. We evaluated the implementation of the protocol and the prediction of HPV testing as a triage tool for
cervical intraepithelial lesions grade two or worse (CIN2+) in women with a cytological diagnosis of ASC-US.
Methods: During 2007-08 a total of 611 women from five reference laboratories in Catalonia with a novel
diagnosis of ASC-US were referred for high risk HPV (hrHPV) triage using high risk Hybrid Capture version 2. Using
routine record linkage data, women were followed for 3 years to evaluate hrHPV testing efficacy for predicting
CIN2+ cases. Logistic regression analysis was used to estimate the odds ratio for CIN2 +.
Results: Among the 611 women diagnosed with ASC-US, 493 (80.7%) had at least one follow-up visit during the
study period. hrHPV was detected in 48.3% of the women at study entry (mean age 35.2 years). hrHPV positivity
decreased with increasing age from 72.6% among women younger than 25 years to 31.6% in women older than
54 years (p < 0.01).
At the end of the 3 years follow-up period, 37 women with a diagnosis of CIN2+ (18 CIN2, 16 CIN3, 2 cancers, and
1 with high squamous intraepithelial lesions -HSIL) were identified and all but one had a hrHPV positive test at
study entry. Sensitivity to detect CIN2+ of hrHPV was 97.2% (95%confidence interval (CI) = 85.5-99.9) and specificity
was 68.3% (95%CI = 63.1-73.2). The odds ratio for CIN2+ was 45.3 (95% CI: 6.2-333.0), when among ASC-US hrHPV
positive women were compared to ASC-US hrHPV negative women.
Conclusions: Triage of ASC-US with hrHPV testing showed a high sensitivity for the detection of CIN2+ and a high
negative predictive value after 3 years of follow-up. The results of this study are in line with the current guidelines
for triage of women with ASC-US in the target age range of 25-65. Non adherence to guidelines will lead to
unnecessary medical interventions. Further investigation is needed to improve specificity of ASC-US triage.
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Background
Invasive cervical cancer (ICC) is the third most common
tumor in women worldwide. Persistent infection with
high risk Human Papillomavirus types (hrHPV) is con-
sidered a necessary cause for the development of ICC
[1,2].
Cytology based cervical cancer (CC) screening has
been fundamental in decreasing the incidence and mor-
tality of cervical cancer in those countries with high
screening coverage rates [3]. One of the most common
abnormal diagnoses identified in cytology based cervical
screening of asymptomatic women is atypical squamous
cells of undetermined significance (ASC-US). The per-
centage of cytological results reporting the presence of
ASC-US ranges from 5% in the USA to 2% in Sweden
[3-6]. The management of ASC-US generally includes
referral to colposcopy, with its subsequent cost and
patient anxiety. Colposcopy examination should there-
fore be performed only in cases of clear clinical benefits.
Data are now consistent in showing that triage with
hrHPV DNA using Hybrid Capture 2 (HC2, Qiagen,
Baltimore, USA) results in a higher sensitivity with a
small decrease in specificity for cervical intraepithelial
lesions grade 3 (CIN3) when compared to repeated
cytology [3,5,7-10]. Most clinical algorithms for the
triage of ASC-US triage now involve HPV testing [8-10].
Catalonia is a region in the North-East part of Spain
with a population of 2,802,504 million women aged 25
and above in 2008. The incidence of ICC in 2008 was 7
per 100,000 representing 2.7% of all cancer cases in the
region [11]. As in other regions of Spain, cervical cytol-
ogy is recommended as the primary screening preven-
tive strategy for ICC. This is offered under an
opportunistic frame within the public sector. The cover-
age of screening cytology is estimated to be around
50-70%[12-14].
In 2006, HPV DNA testing for high risk types using
Hybrid Capture version 2 (hrHC2) was introduced on a
regular basis for the triage of ASC-US. The main aim of the
present study was to evaluate, for the first time in Spain,
the value of hrHPV as a predictor marker of CIN2+ lesions.
Methods
Public health in Catalonia is free of direct charge for the
population and provides full access to medical care and
cancer screening interventions. About 70% of the gynae-
cological care in the population of Catalonia is carried
out within the Public Sector.
In Catalonia, from June 2006 to October 2007 a new
screening protocol for CC in sexually active women
aged 25-65 years was implemented to increase coverage
and to reach a 3 years interval between screening cytol-
ogies [14]. Younger women could also benefit of ICC
screening after 3 years of sexual initiation. Further,
women became eligible for hrHPV testing under the fol-
lowing circumstances: i) having an incident diagnosis of
ASC-US; ii) being aged 40 years or more and having a
poor cervical cancer screening history with no Pap
smear in the previous 5 years, and iii) first follow up
visit after a surgical conization. In the present study we
reviewed the intervention among ASC-US cases. Evalua-
tion of ii and iii is ongoing.
Primary care doctors and midwives were regularly
required to evaluate the adequate compliance of women
to the general screening recommendations detailed in
the protocol.
As per protocol, follow-up of women with a screening
cytological result of ASC-US in the absence of liquid-
based cytology included recommendation for another
cervical cells sample to evaluate the presence of high
risk hrHPV within a 3 months period from the initial
result. Follow-up after a 3 year interval was recom-
mended for those women with negative hrHPV test
results. For those women with positive hrHPV test
result referral to colposcopy and biopsy (if appropriate)
were recommended.
A total of 37,711 hrHPV tests were performed within
2007-2008 in the context of the population based
screening protocol in Catalonia. Of these, 5,861 hrHPV
tests were among women with a diagnosis of ASC-US.
Among all participant centres, eight pre-defined geogra-
phical areas were selected for protocol monitoring: Baix
Llobregat litoral, Osona, Bages, Berguedà, Solsonès, Sant
Martí and Ciutat Vella districts of city of Barcelona,
Gironès - Plà d’Estany and Tarragonès. Participating
centers were consistent with the distribution of the
urban/rural balance of the population in whole
Catalonia.
HPV tests were performed in five referral laboratories.
All of them followed an external quality control (QC)
for the performance of hrHC2 testing. The Catalan
Institute of Oncology was in charge of coordinating the
QC. The QC analysis resulted in very high performance
in all the laboratories (data not shown). The overall pro-
ject was approved by the ethical committee of the Cata-
lan Institute of Oncology.
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HPV DNA testing was conducted by five reference
laboratories: Josep Trueta Hospital, Hospital Consortium
of Vic, University Hospital of Tarragona Joan XXIII, Hos-
pital del Mar, Bellvitge University Hospital. HPV detec-
tion was performed using hrHC2 tests (HC2, Qiagen,
Baltimore, USA) which detect 13 high risk oncogenic
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
and 68). An HPV sample was considered positive if it
attained or exceeded the Federal Drug Administration
(FDA)-approved threshold of 1.0 pg HPV DNA ml
-1,
which corresponds to 1.0 relative light unit (RLU/CO).
Cervical cytologies were taken with conventional Pap
smears or with liquid based cervical cytology and pro-
cessed and read at the routine pathology centres. All the
cytology results followed the 2001 Bethesda System [15]
and they were classified as: 1) negative for intraepithelial
lesion or malignancy, 2) ASC-US, atypical squamous cells
cannot exclude a high grade squamous intraepithelial
lesion (ASC-H), 3) low-grade squamous intraepithelial
lesion (LSIL) encompassing human papillomavirus/mild
dysplasia/cervical intraepithelial neoplasia (CIN) 1, 4)
high-grade squamous intraepithelial lesion (HSIL)
encompassing: moderate and severe dysplasia, carcinoma
in situ, CIN 2 and CIN 3; 5) squamous cell carcinoma,
atypical glandular cells (AGC) (specify endocervical,
endometrial, or not otherwise specified), atypical glandu-
lar cells, favor neoplastic (specify endocervical or not
otherwise specified), endocervical adenocarcinoma in situ
(AIS) and adenocarcinoma.
For the histological diagnosis, the protocol guidelines
recommended the use of CIN classification [16].
Follow-up
All histological, cytological and molecular data of cases
diagnosed with ASC-US were collected and evaluated to
its final worse diagnosis using a record linkage approach
based on the medical record number of the women.
Once the information was available, all patient data were
anonymised. Those women with negative hrHPV test
after ASC-US diagnosis should be recommended a follow
up visit in a 3 year interval. When a woman had any
abnormal consecutive pathology test result after the
initial ASC-US, the final diagnosis was the worst during
the period and censored at the time of treatment, if any.
In these later cases the assignment to a final diagnosis
was based on the result of the biopsy before treatment.
For those women with initial HPV positive test results, a
final diagnosis of ‘normal’ was reported in patients with
1) two negative consecutive cytological samples, 2) two
negative consecutive cervical biopsies, or 3) one negative
cytological sample and one negative cervical biopsy
within a 1 year interval or a second hrHPV negative test
result. For those women with hrHPV negative results, a
final diagnosis of “normal” w a sr e p o r t e di fa tl e a s to n e
test result was negative at the end of follow up period.
When both cytological and histological specimens were
collected at the same time, the worst histological
abnormality result was reported as final diagnosis.
Statistical analysis
Data analyses were carried out using SPSS version 17.0.
Age was grouped into five categories: < 25, 25-34, 35-44,
and 45-54 and ≥ 54 years old. The relative light units/cut
off (RLU/CO) was divided into nine categories: 0-0.5,
0.6-0.99, 1-1.99, 2-49, 50-99, 100-499, 500-999, 1000-
1999, ≥ 2000. Sensitivity, specificity, positive predictive
value (PPV), negative predictive value (NPV) were esti-
mated together with exact 95% CI, one or two sided as
appropriate. When appropriate, comparison between
categories was performed with a t-test for continuous
variables and a chi square test for categorical variables.
Finally, a logistic regression analysis adjusted by age and
centre was performed in order to calculate the odds ratio
of developing a CIN2+ lesion as a function of hrHPV sta-
tus at study entry. The analysis was performed as a cross-
sectional evaluation at the end of the first round of
screening.
Results
During 2007 and 2008, 65,378 women from the study
population were screened with conventional cytology and
a total of 69,952 Pap smears were obtained. Out of them,
95% were negative for cervical intraepithelial lesion or
malignancy, 2% were reported as ASC-US/atypical gland-
ular cells of undetermined significance (AGUS), 0.08%
were reported as atypical squamous cells-cannot exclude
HSIL (ASC-H), 2% were reported as LSIL, 0.3% were
reported as HSIL and 0.03% were suspected of cancer.
613 ASC-US cases that had a concomitant hrHPV testing
were included in the present study (76 from the counties
of Osona, Bages, Berguedà and Solsonès, 105 from the
counties of Gironès and Pla de l’Estany, 213 from the
counties of Baix Llobregat Litoral, 151 from the Barce-
lona districts of Sant Martí and Ciutat Vella and 68 from
the county of Tarragonès). Two cases were excluded: one
with history of vaginal cancer and the other with endo-
metrial cancer. The final sample size for the analyses was
of 611 women. All the hrHPV tests were performed
within a maximum period of 6 months after ASC-US
diagnosis. The 68 cases of Tarragonès were included
despite of being diagnosed in 2008 because follow-up
was available for the majority of the women (81%).
The mean age of ASC-US cases was 35.4 years (stan-
dard deviation (SD) = 11.3) ranging from 15 to 79 years
(Table 1). Follow-up information was available for 493
women (80.7% of the total sample). There was no differ-
ence in the age distribution of women with and without
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more likely to have a hrHPV positive test result (48.3%)
in comparison with ASC-US hrHPV negative women
(51.7%, p = 0.02).
Table 2 shows the final diagnosis at the end of the fol-
low-up period by initial HPV DNA result. Among
hrHPV positive cases, 45.4% had a final diagnosis of
negative for CIN, 15.5% remained hrHPV positive with
no other cytological abnormality, and 14.4% had a diag-
n o s i so fH S I L - C I N 2 +( 3 6o u to f2 3 8 ) .O n es q u a m o u s
carcinoma (stage 2) and one mucinous adenocarcinoma
(stage 3) were also identified in this group. On the con-
trary, among HPV negative women, 91.4% had a final
diagnosis of negative for CIN and one case (0.4%) was
diagnosed as CIN2. Further verification of this case
showed a p16
INK immunochemistry positive test result
suggestive of an HPV driven lesion. No sample was
available for further testing.
The sensitivity of hrHC2 for the detection of histologi-
cally confirmed CIN2+ was of 97.2% (CI = 85.5-99.9)
(35/36); and of 100% (CIone sided = 82.9) for CIN3+ (16/
16). The specificity of hrHC2 for the detection of histo-
logically confirmed CIN2+ was of 68.3% (CI = 63.1-
73.2) (108/341), excluding intermediate diagnoses such
as HPV positivity or LSIL. The NPV of hrHPV test for
CIN2+ was of 99.6% (CIone sided = 98.2) (254/255).
Table 3 shows the distribution of final diagnosis by
age group. The percentage of hrHPV positive cases was
highest among women younger than 25 years (61/84,
72.6%) and declined thereafter (p value for linear trend
< 0.01). The two cancer cases were diagnosed in 51
years old woman and in a 55 years old woman. CIN3
and HSIL cases clustered largely in the age range of 25
to 44 years, while CIN2 cases were mainly observed
among women younger than 34 years old. Among ASC-
US-HPV negative, the only CIN2 case was diagnosed in
a 35 years old woman.
Among hrHPV positive women with a final diagnosis
of CIN2+, 69.4% were diagnosed as CIN2+ at first
biopsy. The remaining cases were diagnosed within the
established 6-12 months follow-up period for women
with ASC-US results and being hrHPV positive and col-
poscopy negative or having a negative biopsy.
hrHPV status at study entry was the only statistical sig-
nificant variable associated to the risk of CIN2+ (p-value
< 0.05). The odds ratio of CIN2+ was 45.3 (95% CI = 6.2-
333.0) when ASC-US hrHPV positive women were com-
pared to that of ASC-US hrHPV negative women.
Among hrHPV positive cases, the lag time from ASC-
US to CIN2+ was shorter and statistically significant in
comparison with the lag time between ASC-US and
other milder diagnostics (11.9 months versus 17.9
months, respectively, p value = 0.002).
Among the 255 ASC-US hrHPV negative women,
85.1% were at least examined once by a gynaecologist
and a cervical smear was taken within the 3 year recom-
mended lag period. The record linkage system identified
321 Pap smears, 34 histological specimens and 56
hrHPV tests performed during that period. The average
lag time from the initial ASC-US HPV negative result to
the next gynaecological test was 1.9 years (SD = 0.94).
Discussion
The results of this study confirm that among women with
a new diagnosis of ASC-US, hrHPV DNA testing clearly
defines the group of women with an underlying high risk
Table 1 General characteristics of women with a diagnosis of ASC-US from 5 sentinel screening centres in Catalonia
(Spain)
CHARACTERISTIC TOTAL WOMEN WITH FOLLOW UP
&
Total cases 611 493
Mean follow up time years - 3.9
Age mean years (range) 35.4(15-79) 35.2(15-71)
Age groups yrs N(%) N(%)
< 25 106(17.3) 84(17.0)
25-34 224(36.7) 182(36.9)
35-44 125(20.4) 100(20.3)
45-54 126(20.6) 108(21.9)
> 54 30(4.9) 19(3.8)
First hrHPV after ASC-US N(%) N(%)
Negative 331(54.2) 255(51.7)
Positive 280(45.8) 238(48.3)*
&Maximum follow up period 3.5 years * p value hetereogeneity test 0.02
ASC-US: Atypical squamous cell of undetermined significance, hrHPV: High risk Human Papillomavirus test
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after a 3 years follow up period. hrHPV testing among
women with ASC-US identified a high number of CIN2+
(37/493) cases conferring a risk of CIN2+ 45 times higher
than the one observed in ASC-US negative women. Sensi-
tivity for CIN2+ was of 97.3% and sensitivity for CIN3+
was of 100%. Specificity for CIN2+ was of 68.3%.
ASC-US is generally described to be more common in
young women than in postmenopausal women [17,18].
In this study, 17% of the ASC-US cases were diagnosed
in women younger than 25 years old. In this age group
HPV was detected in a much larger proportion than in
other age groups (72.6%), suggesting that acute infections
are probably playing a major contribution in this age
Table 2 Diagnosis at last follow up
&among 493 women with ASC-US from 5 sentinel screening centres in Catalonia
(Spain) by hrHPV status
TOTAL CASES POSITIVE hrHPV NEGATIVE hrHPV
Diagnosis at last follow up
&1 NN % N %
Normal 341 108 31.7 233 68.3
No histology confirmation:
ASC-US 13 6 46.2 7 53.8
hrHPV+ 46 37 80.4 9 19.6
CIN-NOS 1 1 100.0 0 0.0
LSIL 33 30 90.9 3 9.1
HSIL* 1 1 100.0 0 0.0
With histology confirmation:
CIN1 22 20 90.9 2 9.1
CIN-2 18 17 94.4 1 5.6
CIN-3 16 16 100.0 0 0.0
Cancer 2 2 100.0 0 0.0
Total 493 238 48.3 255 51.7
&Maximum follow up 3.5 years
1 ASC-US: Atypical squamous cell of undetermined significance, HPV+: positive for Human Papillomavirus test, CIN-NOS: CIN not otherwise specified, CIN1: high
grade cervical intraepithelial lesions grade 1, LSIL: low grade squamous intraepithelial lesion, CIN1: high grade cervical intraepithelial lesions grade 1, CIN2: high
grade cervical intraepithelial lesions grade 2, CIN3: high grade cervical intraepithelial lesions grade 3, HSIL: High grade squamous intraepithelial lesion
* The HSIL case could not be specified as CIN2 or CIN3
Table 3 Distribution of cervical abnormalities at the end of follow-up
&by age and hrHPV status at entry among 493
women with ASC-US from 5 sentinel screening centres in Catalonia (Spain)
AGE
DIAGNOSIS AT LAST FOLLOW UP
&
BY hrHPV STATUS
<2 5N
(%)
25-34
N (%)
35-44
N (%)
45-54
N (%)
>5 4
N (%)
Total
N (% HPV positive)*
84(17) 61(72.6) 182(36.9) 101(55.5) 100(20,3) 38(38.0) 108(21.9) 32(29.6) 19(3.9) 6(31.6)
hrHPV Positive N (%) within diagnostic category
Cancer (N = 2) 0 0 0 1(50.0) 1(50.0)
CIN3/HSIL (N = 17) 3(17.6) 7(41.1) 4(23.5) 3(17.6) 0(0)
CIN2 (N = 17) 5(29.4) 8(47.0) 2(11.8) 1(5.9) 1(5.9)
Other milder diagnosis (N = 94) 19(20.2) 46(48.9) 19(20.2) 9(9.6) 1(1.1)
Normal (N = 108) 34(31.5) 40(37.0) 13(12.0) 18(16.7) 3(2.8)
Total (N = 238) 61(25.6) 101(42.4) 38(15.9) 32(13.4) 6(2.5)
hrHPV Negative N (%) within diagnostic category
CIN 2+ (N = 1) 0 0 1 (100) 0 0
Other milder diagnosis (N = 35) 7(20.0) 10(28.6) 9(25.7) 9(25.7) 0
Normal (N = 220) 16(7.2) 71(32.3) 53(24.1) 67(30.4) 13(5.9)
Total (N = 255) 23(9.0) 81(31.8) 62(24.3) 76(29.8) 13(5.1)
&Maximum follow up period 3.5 years
￿ P value for linear trend < 0.0
CIN2: high grade cervical intraepithelial lesions grade 2, CIN3: high grade cervical intraepithelial lesions grade 3, HSIL: High grade squamous intraepithelial lesion
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among women younger than 25 years old if compared to
the other age groups (3.6% versus 3.9%, respectively). We
cannot exclude that CIN3 lesions in this younger age
group are more likely to regress spontaneously. Any
woman with an ASC-US and hrHPV positive test is
referred to colposcopy and close follow-up, while the
likelihood of developing an ICC is extremely low in
women younger than 25 years old. According to our pro-
tocol guidelines ASC-US, hrHPV positive women with a
negative colposcopy will still need to be visited at 6 and
12 months and be retested for hrHPV at 12 months.
Moscicki et al. [19], in a prospective study of CIN2 in
adolescents and young women (< 25 years old), showed
that frequently CIN2 regressed spontaneously supporting
the conservative approach for this age group.
The majority of women with hrHPV negative values
(91.4%) did not develop any pathology at the end of the
first round of screening. According to previous studies
[8,20,21], hrHPV negative women are very unlikely to
develop a CIN2+ and it has been suggested that screen-
ing intervals would be safe if they are lengthened at least
up to 6 years. Our findings show that a 3 year screening
interval is safe although based on a small sample of
women. hrHPV triage is likely to result in a cost-effective
strategy if screening intervals are kept and diverts women
from colposcopy in hrHPV negative women [10,22].
However, although the sensitivity of hrHC2 was very
high, specificity was relatively low increasing unnecessa-
rily the number of women referred to colposcopy because
of a positive test. There was no indication that levels of
RLU/CO could improve our specificity in the triage of
ASC-US cases. It is likely that in the near future new
triage strategies will improve specificity while keeping
high sensitivity rates [21]. Further, in our study, 65.6%
(217/331) of the total women with ASC-US hrHPV nega-
tive test had at least one follow-up visit before finishing
the first round of screening, meaning that the current
screening protocol recommending follow-up after a 3
years period is not widely subscribed by the professionals.
In view of our data we can conclude that a bulk of addi-
tional tests were unnecessary, thus reducing the potential
cost-effectiveness of the strategy. In addition unnecessary
testing may induce anxiety, worry and discomfort in
these patients.
Our data are consistent with other studies using hrHC2
as a triage test [23-26]. Del Mistro et al. [23] carried out a
study in Veneto region (Italy) among 749 women with
ASC-US cytology in an organized screening programme.
The prevalence of hrHPV infection was of 42.9% and the
mean age of the women in this study was of 42 years old.
CIN2+ developed in 14.9% of the hrHPV positive women
at enrolment and in only 0.35% of the hrHPV negative
women. In our study, with slightly younger women and
similar hrHPV prevalence, 15.1% of the hrHPV positive
women developed a CIN2+ at the end of the follow up
period and only 0.4% of the hrHPV negative women
developed a CIN2+. In the ASCUS and LSIL triage study
(ALTS) [5] which included 1161 ASC-US cases, 50.7%
were hrHPV positive and 16.0% of them developed a
CIN2+. Only 1.4% of the hrHPV negative women devel-
oped a CIN3 after a follow-up period of 2 years. Further-
more, in a study from an organized screening
programme in the county of Gävle (Sweden) [6], hrHPV
prevalence among ASC-US cases was of 50%, and 32.3%
of the hrHPV positive cases and 2.04% of the HPV nega-
tive cases had a CIN2/3. The study results published in
the scientific literature are consistent in observing that
CIN2+ cases are almost universally within the hrHC2
positive category.
The limitations of the present study are that the follow-
up window was slightly over a 3 years period - from Janu-
ary 2007 up to February 2011. Although information
from 80.7% of the women was available, it is possible that
appointments for the remaining ones were fixed later
than the 3 years period. An additional limitation is that
colposcopies among hrHPV negative women were not
randomly carried out. However, a relevant proportion of
these patients obtained negative colposcopy results for
CIN2+ suggesting that verification bias was not affecting
our results. Our data was restricted to information gener-
ated within the public health system serving over 70% of
the gynaecological care. Therefore, we cannot extrapolate
our data to women being attended in the private sector
as they may differ in terms of risk factors from HPV
acquisition or cervical cancer.
In this study we used the information from five senti-
nel centres with available record linkage system and no
detailed medical records were available. We did not
review the pathology diagnosis of the initial cytology of
ASC-US nor the follow-up diagnosis by cytology,
biopsy or hrHPV testing. Therefore, discrepancies
between pathologists in classifying ASC-US cannot be
excluded.
A strength of our study was that information was
retrieved from a public health system in which a com-
mon protocol was introduced and monitored for its ade-
quacy and performance across the different laboratories
and medical centers. The protocol was homogenously
introduced and monitored and coordinated irrespective
of the clinical decisions taken.
Conclusions
HPV DNA testing as a triage test for ASC-US has been
shown to predict CIN2+ lesions and to provide very
high negative predictive value among those cases that
followed the protocol guidelines. This study supports
our current national recommendations for ASC-US
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for younger women entering into screening protocols
need to be re-evaluated. Non adherence to guidelines
will lead to unnecessary medical interventions and psy-
cho-social effects, such as anxiety. Further research is
needed to improve specificity of ASC-US triage.
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